Replies to post #61560 on Xechem International Inc. (fka XKEM)

[Diamond_Dog]

Nice read there gambler,

If I read it correctly they did a phase lll previously, but being it wasn't completed it needed to be done again!

With assistance from various organizations, NIPRISANR, a herbal drug of ethnomedicine source that is used for sickle cell anemia disorder, is in its third clin.-trial

development phase at the National Institute for Pharmaceutical Research and Development, Abuja, Nigeria.


Eighty-four patients met

the inclusion criteria, but complete data were available for only 69 patients at the end of 12 mo, 33 in group A and

36 in group B. Loss to follow-up was related to social and logistic factors rather than study drug. One oral dose of

12 mg/kg niprisan daily significantly reduced the frequency of sickle cell crises, bone pain, and hospital admission (P <

0.05). The mean no. of crises per person per mo was 0.05 in patients who received niprisan initially, compared with

0.11 per person per mo after the crossover to placebo. Patients generally rated their health as better and reported

less sickness and absenteeism with niprisan than with placebo.

http://www.investorshub.com/boards/read_msg.asp?message_id=14454980

This is just what I waas looking for,

Thanks,
&

$$Good Luck$$

J.............

[painkillerdoc]

Taken from the abstract of 2002 from the National Institute for Pharmaceutical Research and Developement you posted earlier.
"one oral dose of 12mg/kg Niprisan daily"
Apart from causing headache, which was reported by 9 patients while taking Niprisan, there were no important adverse effects.
As a counter measure to prevent headache from slightly high dosing.
To date it has been determined that the most effective daily dosage of Nicosan consists of four capsules for adults and two capsules for children. The daily doses should be administered in two divided doses with one-half of the daily dosage taken twice daily. Preferably the seperate divided doses will be taken in the morning and again in the evening.